-
Dechi Pharmaceuticals Selinexor's listing application was accepted by NMPA
Time of Update: 2021-01-29
Deki Pharmaceuticals has recently submitted applications for the listing of selinexor for three types of hematoma adaptations, including multiple myeloma and diffuse large B-cell lymphoma.
, five treatment options for selinexor for multiple myeloma and diffuse large B-cell lymphoma have been included in the Guidelines of the National Comprehensive Cancer Network (NCCN®).
-
End-of-2020 inventory: Cell magazine's breakthrough research
Time of Update: 2021-01-21
to the end of the year, 2020 is nearing the end of the year, welcome us will be a brand-new 2021, 2020 three internationally renowned magazines Cell, Nature and Science (CNS) still published a lot of
-
Nat Immunol: Key proteins are involved in T-cell metabolism and anti-tumor immune response
Time of Update: 2021-01-20
January 5, 2021 // -- Researchers at the University of Texas MD Anderson Cancer Center have found that a protein called NF-B-induced kinase (NIK) is critical to changes in metabolic activity caused by T-cell activation, making it a key factor in regulating T-cell anti-tumor activity.
-
Cladophora
Time of Update: 2021-01-08
Cell walls are extremely thick, often hierarchical, the surface of the layer contains 70 % of the protein , often rough, so that there are often many algae attached to it; Pieces of the silky body, the false roots of the base cells can be nutritional reproduction.
-
First-line immunotherapy for lung cancer! Roche Tecentriq (Tai Sanqi) Japan approved: single-drug first-line treatment PD-L1 high expression NSCLC
Time of Update: 2020-12-31
data from phase III IMpower110 study show that Tecentriq has significant survival benefits compared to chemotherapy in patients with high expression PD-L1 in first-line treatment, significantly extending total lifetime (OS) by 7.1 months (mid-OS): 20.2 months vs 13.1 months, HR=0.595,95%CI:0.398-0.890, p=0.0106).
-
Fengyun male world advanced gastric cancer first-line immunotherapy who and fight
Time of Update: 2020-11-08
KEYNOTE-659 study is a non-randomized, multi-center, open IIb phase study conducted in Japanese population, which evaluated the effectiveness and safety of K-drug combination chemotherapy as HER2-negative, PD-L1-positive advanced GC/GEJC first-line therapy.
-
Cell Death Differ: DAPK3 activates ULK1's dependent autophagy to inhibit the development of stomach cancer
Time of Update: 2020-10-21
ULK1 Ser556 phosphorylation promotes autophagy and tumor suppression of stomach cancer cells mediated by DAPK3 The study found that the tumor suppression function of DAPK3 depends on the autophagy process of cells.
-
NAT COMMUN: No. 1 CRISPR technology targets cancer cells in the body
Time of Update: 2020-10-20
recently, based on CRISPR/Cas9 technology, researchers designed a simple, efficient, non-patient-specific gene editing strategy that allows specific and powerful destruction of FO in cancer cells by targeting two inclusions of genes involved in rearm.
-
Ano Pharmaceuticals AN0025 and Mercadon KEYTRUDA ® phase 1b clinical drug was completed in the United States as the first patient administration
Time of Update: 2020-10-15
The study (AN0025S0103) is an open, multi-center clinical phase 1b trial conducted in the United States and Europe, including dose-limiting toxicity (DLT) observation and expansion phase 2 phases, de
-
Br J Cancer: New non-invasive exhalation test to diagnose early-stage head and neck cancer
Time of Update: 2020-09-23
based on mass spectrometrometrometical analysis, two logic regression models were used to distinguish the respiratory status of cancer patients and 2 (benign disease) patients.
results show that non-invasive respiratory test diagnosis of HNSCC may be a potentially practical and accurate diagnostic method.
-
Selective killing tumor cells, advanced liver cancer, bowel cancer liver metastasis has a new treatment method
Time of Update: 2020-08-16
, Huang Jiaming, director of the Oncology Department of the Hong Kong Health Cancer Center, suggested in the keynote speech "SirT of liver metastasis of colorectal cancer" that SIRT is a selective inthertomerapy, a special radiotherapy, sirT treatment is a special radiation treatment, SIRT treatment is through blood vessels to transport high doses of radioactive particles to a specific location of the body, selectively kill tumor cells, to normal tissues and organs with little harm.
-
The source of citrate in bone microstructures has been identified for the first time
Time of Update: 2020-08-10
in this study, the researchers used liquid and solid nuclear magnetic resonance technology, through 13C isotope marker tracking and targeting metabolomics methods, found that the citrate in the phosphoric acid from the MSC bone differentiation later triamcinic acid cycle process glucose oxidation metabolism intermediate products, and revealed that MSC absorption using zinc ions to regulate the bone differentiation of Runx2/Osterix/ZIP1 molecular signal mechanism, this positive feedback pathway further promotes the formation of citrate and sedimentation.
-
Cell Rep: Discover a new immune target for the flu vaccine! Broad-spectrum influenza vaccine is within reach
Time of Update: 2020-07-31
picture source: Lead author Dr Alex Greenshields-Watson, from The University of Cardiff School of Medicine, said: "Unlike the current vaccine's main target external flu proteins, these internal proteins are highly conservative between different flu strains.
-
ADC research and development pipeline explosion non-cancer indications will become the next "blue sea
Time of Update: 2020-07-30
Another reason for the explosive growth of ADC research and development pipeline by development stage (data source: Cortellis, discovery phase: in vitro experimental phase; pre-clinical: in vivo animal experiment; drug Mingcond content team mapping) indications growth is that the same ADC can be used to treat multiple indications due to the maturity of ADC technology.
-
Nature Sub-Journal: The new team of YuYu Yu of Peking University has revealed a new mechanism for cancer immunity
Time of Update: 2020-07-22
in 2003, Professor Yin Yuxin's research group reported for the first time that PAC1 was involved in the occurrence and development of tumors in nature, and proposed that PAC1, as a phosphatase specifically expressed in the immune system, may participate in the formation and remodeling of tumor microenvironment.
